雷帕鸣怎么样

(Sirolimus tablets) is an immunosuppressant that inhibits the activation and proliferation of T lymphocytes by inhibiting their response to stimulation by antigens and cytokines (IL-2, IL-4 and IL-15).

Rapamune is suitable for patients aged 13 or above who have received kidney transplants to prevent organ rejection. Rapamune is recommended for use in combination with cyclosporine and corticosteroids. Monitoring of therapeutic drug plasma concentrations is recommended for all patients receiving rapamycin.

How about Indian Biokang Lepa Ming?

Model animal test results show that rapamin (sirolimus tablets) can prolong the survival of allografts (kidney, heart, skin, pancreatic islets, small intestine, pancreatico-duodenum and bone marrow) in mice, rats, pigs and/or primates. Sirolimus reverses acute rejection of cardiac and renal allografts in rats and prolongs graft survival in presensitized rats. In some studies, the immunosuppressive effects of sirolimus persisted for up to 6 months after stopping treatment. This immune tolerance effect is alloantigen specific.

It should be noted that grapefruit juice can slow down the metabolism of rapamin (sirolimus tablets) regulated by CYP3A4, and therefore cannot be used for administration or dilution of this drug. Use is prohibited if the patient is allergic to sirolimus, sirolimus derivatives, or any component of rapamin (sirolimus tablets) oral solution. Pregnant and nursing women should not use rapamycin (sirolimus tablets) because it may cause harm to the fetus.

The price of the original drug is relatively high, which is a big burden for patients who need to take the drug for long-term treatment. Many patients choose India's Biocon Repamin. Biocon India is one of the three largest biotechnology companies in India and an emerging global biopharmaceutical company. If patients want to purchase the cost-effective Rapamin, they can consult with domestic reliable overseas medical service organizations (such as Medical Companion Travel).

Recommended related hot articles: /newsDetail/86944.html